Microecological Control of Antimicrobial Resistance Using CRISPR-Based Precision Interventions

Conventional antimicrobial treatment is limited by genetically active reservoirs of resistomes in humans that propagate antimicrobial resistance genes regardless of antibiotic dosage. Interconnected microbiomes gather, spread, and protect resistance genes, making antimicrobial resistance a potential global issue. Broad-spectrum antibiotics disrupt microbial ecology, increase selective pressure, and hasten horizontal gene transfer, hence augmenting genetic resistance. Maintaining the health of microbial populations is crucial while managing resistance factors. This unique CRISPR-Cas-based technique for controlling antimicrobial resistance focuses on resistance genes, virulence factors, and mobile genomic elements while keeping bacteria alive. Our current study explores that native CRISPR immunity reduces plasmid acquisition and resistome expansion; yet, many clinically effective infections lack functional CRISPR systems, suggesting an evolutionary trade-off that favors resistance over immune defense. This ecological perspective guides our critical evaluation of engineered CRISPR-based antimicrobials administered by bacteriophages, conjugative plasmids, nanoparticles, and engineered probiotics to eradicate resistance plasmids, resensitize multidrug-resistant infections, and reduce pathogenicity. Mechanistic and in vivo studies have shown that CRISPR lowers the resistance load and escape pressure in Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus aureus, and viruses. The hurdles in designing CRISPR include poor microbiome ecology, delivery effectiveness, anti-CRISPR mechanisms, and transmission through mobilome. Our microecological framework employs CRISPR technologies as resistome-modulating adjuvants to maintain antibiotic efficacy, rather than relying solely on antimicrobials. CRISPR-based medicines revolutionize how antibiotic resistance is regulated considering AMR possesses been linked with genetic flow and ecological balance. • Antimicrobial resistance is reframed as a microecological problem driven by resistome and mobilome dynamics. • Native and engineered CRISPR–Cas systems selectively modulate resistance gene flow while preserving microbiome structure. • CRISPR-based antimicrobials function as resistome-modulating adjuvants rather than broad-spectrum bactericidal agents. • Phage, conjugative plasmid, and nanoparticle platforms enable ecological deployment of CRISPR across microbial communities. • Integrating microbiome ecology with CRISPR engineering offers a sustainable strategy for precision AMR management.